Internal Medicine · Southgate, MI
NPI
1174553770
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3 Heritage Dr, Suite 1
Southgate, MI, 48195
Phone (734) 283-3222
Groups this clinician bills Medicare through
Medicare paid, 2024
$128K
2,610 services
Medicare patients, 2024
237
Average age 70
Drug cost, 2024
$1.9M
14,917 prescriptions
Company payments, 2025
$2,382
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Neshewat was code 99214 (office e&m - established), 483 times for 174 patients. In total Michael Neshewat billed 2,610 services in 92 codes, and Medicare paid $128K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-01-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 483 | 174 | $93.28 | $45K |
| 99213 Office E&M - Established | Office | 243 | 115 | $67.60 | $16K |
| 96372 Injection Administration | Office | 190 | 59 | $11.41 | $2,169 |
| G0136 Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes | Office | 125 | 118 | $7.92 | $990 |
| 81002 Clinical Chemistry | Office | 118 | 88 | $3.41 | $402 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 108 | 24 | $0.54 | $57.79 |
| 71046 X-ray - Chest | Office | 98 | 92 | $24.07 | $2,359 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 97 | 35 | $0.89 | $86.66 |
| 93000 Electrocardiogram | Office | 80 | 74 | $10.87 | $869 |
| 82043 Clinical Chemistry | Office | 76 | 74 | $5.66 | $430 |
| 99232 Hospital E&M - Subsequent | Facility | 74 | 14 | $67.54 | $4,998 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 69 | 69 | $139.91 | $9,654 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 66 | 66 | $20.14 | $1,329 |
| G0008 Administration of influenza virus vaccine | Office | 61 | 60 | $29.40 | $1,793 |
| 90656 Vaccine Product | Office | 60 | 60 | $21.90 | $1,314 |
By year: 2022 $139K for 2,797 services; 2023 $134K for 2,785 services; 2024 $128K for 2,610 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 118 | 88 | $3.41 | $402 |
| 82043 Clinical Chemistry | 76 | 74 | $5.66 | $430 |
| 82570 Clinical Chemistry | 48 | 47 | $1.96 | $94.08 |
| 87804 Immunoassay | 24 | 17 | $16.22 | $389 |
| 87811 Immunoassay | 20 | 17 | $38.22 | $764 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael Neshewat prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 712 prescriptions and refills. In total Michael Neshewat wrote 14,917 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 712 | 722 | 128 | $11K |
| Atorvastatin Calcium Generic | 364 | 973 | 108 | $5,115 |
| Rosuvastatin Calcium Generic | 325 | 902 | 95 | $5,841 |
| Amlodipine Besylate Generic | 311 | 782 | 95 | $2,000 |
| Pantoprazole Sodium Generic | 309 | 741 | 89 | $4,794 |
| Metformin Hcl Generic | 302 | 803 | 95 | $18K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 282 | 282 | 56 | $4,986 |
| Metoprolol Succinate Generic | 279 | 674 | 73 | $4,207 |
| Pravastatin Sodium Generic | 245 | 674 | 79 | $3,450 |
| Losartan Potassium Generic | 245 | 695 | 78 | $3,713 |
| Levothyroxine Sodium Generic | 235 | 660 | 71 | $3,025 |
| Fluticasone Propionate Generic | 226 | 388 | 65 | $3,189 |
| Famotidine Generic | 222 | 324 | 52 | $49K |
| Gabapentin Generic | 214 | 291 | 52 | $2,067 |
| Omeprazole Generic | 210 | 553 | 70 | $3,435 |
Brand drugs: 1,597 claims; generic drugs: 13,147 claims; opioid claims: 1,300.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Neshewat $2,382 ($2,382 in general payments such as food, travel and fees) from 28 companies. The largest payer was Abbvie Inc. with $285.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 13 | $285 |
| Pfizer Inc. PFE | 10 | $275 |
| Lilly USA, LLC LLY | 14 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 14 | $233 |
| Novo Nordisk Inc NVO | 8 | $148 |
| Shionogi Inc 4507.T | 5 | $143 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 7 | $135 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $94.57 |
| Aimmune Therapeutics, Inc. | 4 | $70.89 |
| Paratek Pharmaceuticals, Inc. | 4 | $70.51 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.